» Articles » PMID: 35508757

Stem Cell Differentiation into Cardiomyocytes: Current Methods and Emerging Approaches

Overview
Publisher Springer
Specialty Cell Biology
Date 2022 May 4
PMID 35508757
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular diseases (CVDs) are globally known to be important causes of mortality and disabilities. Common treatment strategies for CVDs, such as pharmacological therapeutics impose serious challenges due to the failure of treatments for myocardial necrosis. By contrast, stem cells (SCs) based therapies are seen to be promising approaches to CVDs treatment. In such approaches, cardiomyocytes are differentiated from SCs. To fulfill SCs complete potential, the method should be appointed to generate cardiomyocytes with more mature structure and well-functioning operations. For heart repairing applications, a greatly scalable and medical-grade cardiomyocyte generation must be used. Nonetheless, there are some challenges such as immune rejection, arrhythmogenesis, tumorigenesis, and graft cell death potential. Herein, we discuss the types of potential SCs, and commonly used methods including embryoid bodies related techniques, co-culture, mechanical stimulation, and electrical stimulation and their applications, advantages and limitations in this field. An estimated 17.9 million people died from CVDs in 2019, representing 32 % of all global deaths. Of these deaths, 85 % were due to heart attack and stroke.

Citing Articles

Recent Insights into Endogenous Mammalian Cardiac Regeneration Post-Myocardial Infarction.

Fiorino E, Rossin D, Vanni R, Aubry M, Giachino C, Rastaldo R Int J Mol Sci. 2024; 25(21).

PMID: 39519298 PMC: 11546116. DOI: 10.3390/ijms252111747.


Bioengineering Approaches and Novel Biomaterials to Enhance Sternal Wound Healing after Cardiac Surgery: A Crosstalk between Innovation and Surgical Practice.

Ferrisi C, Loreni F, Nenna A, Giacinto O, Lusini M, Chello M J Funct Biomater. 2024; 15(9).

PMID: 39330230 PMC: 11432903. DOI: 10.3390/jfb15090254.


A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies.

Netala V, Teertam S, Li H, Zhang Z Cells. 2024; 13(17.

PMID: 39273041 PMC: 11394358. DOI: 10.3390/cells13171471.


Recent Advances in Nanomaterials for Modulation of Stem Cell Differentiation and Its Therapeutic Applications.

Kim C, Koo K, Kim H, Kim T Biosensors (Basel). 2024; 14(8).

PMID: 39194636 PMC: 11352443. DOI: 10.3390/bios14080407.


Engineered heart tissue: Design considerations and the state of the art.

Gokhan I, Blum T, Campbell S Biophys Rev (Melville). 2024; 5(2):021308.

PMID: 38912258 PMC: 11192576. DOI: 10.1063/5.0202724.


References
1.
Roth G, Johnson C, Abajobir A, Abd-Allah F, Abera S, Abyu G . Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017; 70(1):1-25. PMC: 5491406. DOI: 10.1016/j.jacc.2017.04.052. View

2.
Han J, Zhao C, Cai J, Liang Y . Comparative efficacy of vitamin supplements on prevention of major cardiovascular disease: Systematic review with network meta-analysis. Complement Ther Clin Pract. 2020; 39:101142. DOI: 10.1016/j.ctcp.2020.101142. View

3.
Mendis S, Lindholm L, Anderson S, Alwan A, Koju R, Onwubere B . Total cardiovascular risk approach to improve efficiency of cardiovascular prevention in resource constrain settings. J Clin Epidemiol. 2011; 64(12):1451-62. DOI: 10.1016/j.jclinepi.2011.02.001. View

4.
Barabasi A, Gulbahce N, Loscalzo J . Network medicine: a network-based approach to human disease. Nat Rev Genet. 2010; 12(1):56-68. PMC: 3140052. DOI: 10.1038/nrg2918. View

5.
Groarke J . Cardiovascular vulnerability of childhood cancer survivors: time to progress from risk observation to risk modification. Eur Heart J. 2018; 39(17):1563-1566. DOI: 10.1093/eurheartj/ehy099. View